XNW4107, Imipenem/Cilastatin

DRUG2 trials

Sponsors

Evopoint Biosciences Inc.

Conditions

Bacterial Infections

Phase 1

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

CompletedNCT04787562

Evopoint Biosciences Inc.Bacterial Infections

Start: 2021-02-25End: 2022-02-28Updated: 2023-02-16

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

CompletedNCT04802863

Evopoint Biosciences Inc.Bacterial Infections

Start: 2021-03-25End: 2021-09-30Updated: 2023-02-16

Related Papers

Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin

Antimicrobial Agents and Chemotherapy2026-08-27

Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects

Antimicrobial Agents and Chemotherapy2026-06-15